InnovoCommerce/SAFE-BioPharma Form Strategic Relationship
News Jun 27, 2013
The global SAFE-BioPharma® digital identity and signature standard is being incorporated into the InnovoCommerce® eClinical product suite used by many of the world’s largest pharmaceutical companies for their enterprise and investigator portal initiatives. InnovoCommerce is a leading source of innovative eClinical collaboration products and solutions. It also has joined SAFE-BioPharma Association’s Vendor-Partner program.
“Standardized identity management is essential to effective trial collaboration,” said Daniel O’Connor, President and Chief Business Officer, InnovoCommerce. “Making innovoPOINT compliant with the SAFE-BioPharma standard will allow sponsor companies to manage collaborative exchanges with sites, enabling greater productivity, quality and compliance.” innovoPOINT® is the company’s clinical investigator portal commercial off-the-shelf product.
SAFE-BioPharma Association is the non-profit industry coalition responsible for the ongoing development and implementation of the SAFE-BioPharma standard. High assurance digital identity credentials based on the SAFE-BioPharma standard are used in the biopharmaceutical and healthcare sectors to sign electronic documents and data files and to authenticate to online applications. Association members include Abbott, Astellas, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Merck, Pfizer, Roche and Sanofi.
The standard is being incorporated into innovoPOINT, which helps pharmaceutical companies achieve the external collaboration required to successfully manage increasingly complex, globally distributed clinical trials in a cost-effective and efficient manner. innovoPOINT solutions are available via a robust virtual private cloud or on premise.
“We welcome InnovoCommerce as part of the new wave of vendor partners adapting their products and services to support the SAFE-BioPharma standard and the security and efficiency benefits the standard delivers to our growing membership of biopharmaceutical and healthcare companies,” said Mollie Shields-Uehling, President and CEO, SAFE-BioPharma Association.
Organizations looking to benefit from the artificial intelligence (AI) revolution should be cautious about putting all their eggs in one basket, a study published in Nature Machine Intelligence has found. Researchers found that contrary to conventional wisdom, there can be no exact method for deciding whether a given problem may be successfully solved by machine learning tools.READ MORE